Respiratory Syncytial Virus: What is the Risk Over 60?
Makaleler > Tam Makale · 2024
Yazarlar: Oğuzhan Acet, Şükrü Dirik, Arda Kaya, Gökhan VATANSEVER, Ayşe Merve Parmaksızoğlu Aydın, Candan ÇİÇEK, Meltem TAŞBAKAN
Journal of Global Antimicrobial Resistance, Uluslararası, Scopus, 2024, cilt 39, ss 79-79
DOI: 10.1016/j.jgar.2024.10.257
Özet
This study aims to determine the burden of Respiratory Syncytial Virus (RSV) on people aged over 60 at a tertiary health center. RSV affects children, individuals with health conditions, and those aged over 60. Vaccination is advised for at-risk groups to reduce illness and death. We included patients aged over 60 with respiratory infections between 01.01.2015 and 31.12.2023, who tested positive for RSV (A or B) via PCR. We recorded age, gender, symptoms, outpatient/inpatient status, ICU history, pneumonia, chronic diseases, vital signs, lab results, and survival data at one week, one month, and three months. Survival data were compared by gender using chi-square, with p<0.05 considered significant. Figure 1 shows test numbers and positivity rates. Among positive cases, 68 patients (5.69%) were aged over 60, with 32 (47.05%) female. Average age was 70.72 ± 8.84 years. RSV PCR was positive in 7 (10.2%) outpatients and 61 (89.7%) inpatients. Thirty-five (51.4%) had pneumonia. Mean leukocyte count was 9.12 ± 5.35 × 10³/µL, neutrophil count was 6.80 ± 4.33 × 10³/µL, lymphocyte count was 1.32 ± 0.94 × 10³/µL, and CRP levels were 93.7 ± 10.38 mg/L. Twenty-five (36.7%) required ICU care. Common symptoms were cough (56, 82.3%), fever (38, 55.8%), sputum (34, 50%), and shortness of breath (32, 47.05%). Table 1 shows variable distribution by gender. RSV can cause severe comorbidities and death in those aged over 60. Prevention programs are essential to reduce RSV-related mortality and morbidity. This study provides data on RSV burden in this group.